KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inovio Pharmaceuticals (INO) Long-Term Investments (2016 - 2020)

Historic Long-Term Investments for Inovio Pharmaceuticals (INO) over the last 12 years, with Q4 2020 value amounting to $434387.0.

  • Inovio Pharmaceuticals' Long-Term Investments changed N/A to $434387.0 in Q4 2020 from the same period last year, while for Dec 2020 it was $434387.0, marking a year-over-year change of. This contributed to the annual value of $434387.0 for FY2020, which is N/A changed from last year.
  • Latest data reveals that Inovio Pharmaceuticals reported Long-Term Investments of $434387.0 as of Q4 2020.
  • Inovio Pharmaceuticals' 5-year Long-Term Investments high stood at $22.4 million for Q1 2016, and its period low was $434387.0 during Q4 2020.
  • Over the past 5 years, Inovio Pharmaceuticals' median Long-Term Investments value was $9.1 million (recorded in 2017), while the average stood at $10.6 million.
  • Its Long-Term Investments has fluctuated over the past 5 years, first soared by 12448.07% in 2016, then crashed by 5772.06% in 2017.
  • Over the past 5 years, Inovio Pharmaceuticals' Long-Term Investments (Quarter) stood at $16.1 million in 2016, then tumbled by 43.5% to $9.1 million in 2017, then decreased by 29.63% to $6.4 million in 2018, then decreased by 0.9% to $6.3 million in 2019, then plummeted by 93.13% to $434387.0 in 2020.
  • Its Long-Term Investments stands at $434387.0 for Q4 2020, versus $957567.0 for Q3 2020 and $2.7 million for Q2 2020.